AKT1 and melanoma: GDC-0068 (Ipatasertib) is another oral ATP-competitive pan-AKT inhibitor that blocks AKT signaling in a number of cancers, including ovarian, prostate, breast, glioblastoma, colorectal, NSCLC, and melanoma.